13F Pro13F Pro

DIADEMA PARTNERS LP

Institutional InvestorSimilar funds →SEC EDGAR: CIK 2026172
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare92.9%$263.0M
  • Other7.1%$20.1M
  • Financials0.0%$102,479

AUM History

13fpro.ai/research/fund/diadema-partners-lp-2026172

Conviction and streaks

Concentrating · top 10 = 62.5%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

RVMD$RVMDConviction hold9.2% weight · held 5 quartersABVX$ABVXConviction hold7.6% weight · held 4 quartersCOGT$COGTConviction hold6.8% weight · held 7 quartersBMRN$BMRNConviction hold6.3% weight · held 6 quartersVKTX$VKTXConviction hold6.1% weight · held 6 quartersABVX$ABVXAccumulating+293% shares · 3 quarters runningCOGT$COGTAccumulating+405% shares · 3 quarters runningPRQR$PRQRAccumulating+487% shares · 3 quarters runningUTHR$UTHRAccumulating+430% shares · 2 quarters runningRVMD$RVMDAccumulating+276% shares · 2 quarters runningJNJ$JNJTrimming-67% shares · 2 quarters runningANNX$ANNXTrimming-92% shares · 2 quarters runningMNKD$MNKDTrimming-95% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/diadema-partners-lp-2026172

DIADEMA PARTNERS LP 13F holdings — Q2 2026

$791.3M portfolio (+34.6% QoQ) · 149 holdings · Q2 2026 13F · top 10 are 63% of the stock portfolio

Includes $508.2M of put/call options ($179.1M puts, $329.0M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $283.2M. Weights use the stock portfolio.

All holdings — DIADEMA PARTNERS LP (Q2 2026)

149 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
VKTX$VKTXCALLViking Therapeutics, Inc.$47.6M+85%
ABVX$ABVXCALLAbivax S.A.$46.5M+249%
BMY$BMYCALLBRISTOL MYERS SQUIBB CO$34.6MNew
ABVX$ABVXPUTAbivax S.A.$33.6M+152%
BMY$BMYPUTBRISTOL MYERS SQUIBB CO$19.0MNew
CORT$CORTCALLCORCEPT THERAPEUTICS INC$17.9M+30%
KYMR$KYMRCALLKymera Therapeutics, Inc.$17.2MNew
NVS$NVSPUTNOVARTIS AG$15.7MNew
QURE$QUREPUTuniQure N.V.$13.8M—
VKTX$VKTXPUTViking Therapeutics, Inc.$13.7MNew
BIIB$BIIBCALLBIOGEN INC.$13.0MNew
CAPR$CAPRPUTCAPRICOR THERAPEUTICS, INC.$12.9M-14%
SMMT$SMMTCALLSummit Therapeutics Inc.$12.5MNew
LLY$LLYPUTELI LILLY & Co$12.0MNew
INCY$INCYPUTINCYTE CORP$11.9M—

What changed in Q2 2026

Against the previous quarter's 13F: 67 new, 35 added to, 25 trimmed, 62 sold out. Share-count changes; largest moves by dollar size first.

New positions (67)

  • BMY$BMYCALLBRISTOL MYERS SQUIBB CO$34.6M

    first bought this quarter

  • BMY$BMYPUTBRISTOL MYERS SQUIBB CO$19.0M

    first bought this quarter

  • KYMR$KYMRCALLKymera Therapeutics, Inc.$17.2M

    first bought this quarter

  • NVS$NVSPUTNOVARTIS AG$15.7M

    first bought this quarter

  • VKTX$VKTXPUTViking Therapeutics, Inc.$13.7M

    first bought this quarter

  • BIIB$BIIBCALLBIOGEN INC.$13.0M

    first bought this quarter

+61 more in the Excel export

Added to (35)

  • ABVX$ABVXCALLAbivax S.A.+249%

    now $46.5M

  • VKTX$VKTXCALLViking Therapeutics, Inc.+85%

    now $47.6M

  • ABVX$ABVXPUTAbivax S.A.+152%

    now $33.6M

  • UTHR$UTHRUNITED THERAPEUTICS Corp+94%

    now $28.7M · held 3 qtrs, 3 adds in a row

  • ABVX$ABVXAbivax S.A.+115%

    now $21.6M · held 4 qtrs

  • RVMD$RVMDRevolution Medicines, Inc.+72%

    now $26.1M · held 5 qtrs, 2 adds in a row

+29 more in the Excel export

Trimmed (25)

  • CYTK$CYTKPUTCYTOKINETICS INC-85%

    now $2.6M

  • JNJ$JNJJOHNSON & JOHNSON-59%

    now $5.6M · held 3 qtrs, 2 trims in a row

  • MRNA$MRNAPUTModerna, Inc.-37%

    now $7.0M

  • KOD$KODPUTKodiak Sciences Inc.-41%

    now $5.7M

  • VKTX$VKTXViking Therapeutics, Inc.-16%

    now $17.2M · held 6 qtrs

  • CUE$CUECue Biopharma, Inc.-63%

    now $1.5M · held 2 qtrs

+19 more in the Excel export

Sold out (62)

  • VRTX$VRTXCALLVERTEX PHARMACEUTICALS INC / MAwas $41.6M
  • LQDA$LQDACALLLiquidia Corpwas $25.0M
  • UTHR$UTHRCALLUNITED THERAPEUTICS Corpwas $23.8M
  • APGE$APGECALLApogee Therapeutics, Inc.was $18.7M
  • RVMD$RVMDPUTRevolution Medicines, Inc.was $12.2M
  • MRK$MRKPUTMerck & Co., Inc.was $12.0M

+56 more in the Excel export

Firm AUM (Form ADV): $397.9M as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F DIADEMA PARTNERS LP has filed, 6 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow DIADEMA PARTNERS?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of DIADEMA PARTNERS's top 20 holdings: 49/100 (our AI quality score, weighted by position size; 10 of the 20 are scored)

Top 10 since filing

-10.8%

Value-weighted move of the 10 largest stock positions

Turnover

39%

Last quarter; 182% over the last 4

Top 10 weight

63%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

46%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

DIADEMA PARTNERS LP disclosed 149 positions worth $791.3M in its Form 13F-HR for Q2 2026 — $283.2M in common stock plus $508.2M of put/call option positions (reported at underlying notional value, not premium at risk), led by $UTHR (UNITED THERAPEUTICS Corp) at 10.1% of the equity portfolio, followed by $RVMD and $ABVX. During the quarter the fund opened 67 new positions and exited 62 — including a new stake in $BMY and a full exit from $VRTX. The portfolio is most concentrated in Healthcare (92.9% of disclosed assets). All figures are sourced directly from DIADEMA PARTNERS LP’s Form 13F-HR filing with the SEC under CIK 2026172.

Funds like this

managers whose biggest positions overlap DIADEMA PARTNERS's
Vestal Point Capital, LP$4.28B 13F book · 10 shared top holdingsABVXUTHRBMRNRVMDBoxer Capital Management, LLC$1.33B 13F book · 12 shared top holdingsABVXRVMDKYMRKODTCG Crossover Management, LLC$4.16B 13F book · 7 shared top holdingsABVXCOGTRVMDKODBAKER BROS. ADVISORS LP$19.96B 13F book · 9 shared top holdingsRVMDKYMRKODSMMTAvoro Capital Advisors LLC$11.14B 13F book · 5 shared top holdingsUTHRRVMDKYMRQUREOctagon Capital Advisors LP$1.11B 13F book · 8 shared top holdingsABVXCOGTKYMRSMMT

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: DIADEMA PARTNERS LP

13F Pro is an AI hedge fund tracker and stock research platform. For DIADEMA PARTNERS LP (SEC CIK: 2026172), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in DIADEMA PARTNERS LP's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.